Trial · NCT02930018
Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
NCT02930018, Phase 3, Completed, NoNO Inc.; results first posted 2020-12-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke. Trials, record NCT02930018. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02930018
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
- NCT number
- NCT02930018
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,105 participants, actual
- Lead sponsor
- NoNO Inc.
- Conditions
- Stroke, Acute
- Interventions
- Nerinetide (NA-1), 2.6 mg/kg, Placebo
- First posted
- 2016-10-11
- Last updated
- 2022-10-10
- Results first posted
- 2020-12-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects With mRS Score of 0 to 2 | 90 Days | Overall number of subjects experiencing a favorable functional outcome 90 days post-randomization, defined as 0 to 2 on the mRS. The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death. |
| Secondary | Number of Subjects With NIHSS Score of 0 to 2 | 90 Days or the last rating | Number of subjects with good neurological outcome, as defined by a score of 0 to 2 on the NIHSS at Day 90 or the last rating. The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity. |
| Secondary | Mortality Rate | 90 Days | Mortality rate, as defined by event rate (%) for mortality over the 90-day study period |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects With mRS Score of 0 to 2 | 90 Days | Intent-to-Treat Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With NIHSS Score of 0 to 2 | 90 Days or the last rating | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Mortality Rate | 90 Days | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group | 90 days | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group | 90 days or last rating | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Mortality Rate in the No-Alteplase Sub-group | 90 days | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Number of Subjects With mRS Score of 0 to 2 in the Alteplase Sub-group | 90 days | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Number of Subjects With NIHSS Score of 0 to 2 in the Alteplase Sub-group | 90 days or last rating | Participants | COUNT_OF_PARTICIPANTS | |
| POST_HOC | Mortality Rate in the Alteplase Sub-group | 90 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With mRS Score of 0 to 2 | Placebo | 329 | Participants | ||
| Number of Subjects With mRS Score of 0 to 2 | Nerinetide, 2.6 mg/kg | 337 | Participants | ||
| Number of Subjects With NIHSS Score of 0 to 2 | Placebo | 320 | Participants | ||
| Number of Subjects With NIHSS Score of 0 to 2 | Nerinetide, 2.6 mg/kg | 320 | Participants | ||
| Mortality Rate | Placebo | 74 | Participants | ||
| Mortality Rate | Nerinetide, 2.6 mg/kg | 64 | Participants | ||
| Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group | Placebo | 113 | Participants | ||
| Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group | Nerinetide, 2.6 mg/kg | 130 | Participants | ||
| Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group | Placebo | 113 | Participants | ||
| Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group | Nerinetide, 2.6 mg/kg | 129 | Participants |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 556 | |
| Overall Study | STARTED | Nerinetide (NA-1), 2.6 mg/kg | 549 | |
| Overall Study | COMPLETED | Placebo | 550 | |
| Overall Study | COMPLETED | Nerinetide (NA-1), 2.6 mg/kg | 546 | |
| Overall Study | NOT COMPLETED | Placebo | 6 | |
| Overall Study | NOT COMPLETED | Nerinetide (NA-1), 2.6 mg/kg | 3 |
Source ClinicalTrials.gov
Adverse events350
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Placebo | 88 | 554 | |
| other | Headache | Nervous system disorders | Nerinetide, 2.6 mg/kg | 79 | 547 | |
| other | Hemorrhagic Transformation Stroke | Nervous system disorders | Placebo | 66 | 554 | |
| other | Hemorrhagic Transformation Stroke | Nervous system disorders | Nerinetide, 2.6 mg/kg | 60 | 547 | |
| other | Hypotension | Vascular disorders | Placebo | 54 | 554 | |
| other | Hypotension | Vascular disorders | Nerinetide, 2.6 mg/kg | 60 | 547 | |
| other | Urinary tract infection | Infections and infestations | Placebo | 68 | 554 | |
| other | Urinary tract infection | Infections and infestations | Nerinetide, 2.6 mg/kg | 52 | 547 | |
| other | Vascular procedure complication | Injury, poisoning and procedural complications | Placebo | 54 | 554 | |
| other | Vascular procedure complication | Injury, poisoning and procedural complications | Nerinetide, 2.6 mg/kg | 49 | 547 |
1 to 10 of 350Source ClinicalTrials.gov
See all 350 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 74 | 556 |
| Total, all-cause mortality | Nerinetide, 2.6 mg/kg | 64 | 549 |
| Total, other adverse events | Placebo | 472 | 554 |
| Total, other adverse events | Nerinetide, 2.6 mg/kg | 474 | 547 |
| Total, serious adverse events | Placebo | 198 | 554 |
| Total, serious adverse events | Nerinetide, 2.6 mg/kg | 181 | 547 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With NIHSS Score of 0 to 2 in the Alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With mRS Score of 0 to 2 in the Alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Mortality Rate in the No-Alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With mRS Score of 0 to 2 in the No-alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Mortality Rate | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With NIHSS Score of 0 to 2 in the No-Alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: deaths from any cause | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With mRS Score of 0 to 2 | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Mortality Rate in the Alteplase Sub-group | Trial comparisons |
| Nerinetide, 2.6 mg/kg vs Placebo: Number of Subjects With NIHSS Score of 0 to 2 | Trial comparisons |
1 to 10 of 11
See all 11 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02930018
GET https://conductscience.org/api/trials/v1/NCT02930018/events?page=2